medigraphic.com
ISSN 0188-9796 (Print)

2011, Number 4

<< Back Next >>

Rev Endocrinol Nutr 2011; 19 (4)

Vitamin D levels in overweight and obese patients and its association with insulin resistance

Loya-López GM, Godínez-Gutiérrez SA, Chiquete E, Valerdi-Contreras L, Taylor-Sánchez V

Language: Spanish
References: 33
Page: 140-145
PDF size: 77.69 Kb.


ABSTRACT

Background: The interest in vitamin D has recently increased in view of studies that demonstrate insufficient serum concentration in subjects with obesity. Moreover, an association between vitamin D deficiency and metabolic disorders such as diabetes mellitus has been described. Objective: To describe the prevalence of vitamin D deficiency in obese and overweight patients and its association with insulin resistance (IR). Methods: A total of 42 selected patients with overweight/obesity were studied. Differential characteristics of the patients with or without vitamin D deficiency were determined. IR was determined by means of the homeostasis model assessment-insulin resistance (HOMA-IR), and quantitative insulin sensitivity check index (QUICKI). Results: The serum levels of 25-hydroxyvitamin D [25(OH)D] were not associated with a particular body mass index cut-off; however, 25(OH)D levels were low in those with HOMA-IR ≥ 3. This was consistent with a high frequency of cases with levels of 25(OH)D ‹ 20 ng/mL among patients with QUICKI ‹ 0.55. Conclusions: Low levels of 25(OH)D are associated with IR, as it is reflected by HOMA-IR and QUICKI indexes. The somatometric variables did not show any association with serum concentration of this vitamin, which suggests that IR may be a consequence of the low concentrations of vitamin D.


REFERENCES

  1. Herranz A, García M, Álvarez D. Concentraciones deficientes de vitamina D en pacientes con obesidad mórbida. Estudio de caso-control. Endocrinol Nutr 2010; 57: 256-261.

  2. García E. ¿Qué es la obesidad? Rev Endocr Nutr 2004; 12: 88-90.

  3. Parikh S, Edelman M, Uwaifo G, Freedman R, Semega M, Reynolds J, Yanovski J. The relationship between obesity and serum 1,25-dihydroxy vitamin D concentrations in healthy adults. J Clin Endocrinol Metab 2004; 89: 1196-1199.

  4. Ford E, Ajani U, McGuire L, Liu S. Concentrations of serum vitamin D and the metabolic syndrome among US adults. Diabetes Care 2005; 28: 1228-1230.

  5. Hyppönen E, Power C. Vitamin D status and glucose homeostasis in the 1958 british birth cohort : the role of obesity. Diabetes Care 2006; 29: 2244-2246.

  6. Harris S, Dawson-Hughes B. Reduced sun exposure does not explain the inverse association of 25-hydroxyvitamin D with percent body fat in older adults. J Clin Endocrinol Metab 2007; 92: 3155-3157.

  7. Calatayud M, Jódar E, Sánchez R, Guadalix S, Hawkins F. Prevalencia de concentraciones deficientes e insuficientes de vitamina D en una población joven y sana. Endocrinol Nutr 2009; 56: 164-169.

  8. Chiu K, Chu A, Liang V, Saad M. Hypovitaminosis D is associated with insulin resistance and b cell dysfunction. Am J Clin Nutr 2004; 79: 820-825.

  9. Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care 2004; 27: 2813-2818.

  10. Snijder M. van Dam R, Visser M, Deeg V, Dekker J, Bouter L, Seidell J, Lips P. Adiposity in relation to vitamin D status and parathyroid hormone levels: A population-based study in older men and women. J Clin Endocrinol Metab 2005; 90: 4119-4123.

  11. Lu L, Yu Z, Pan A, Hu F, Franco O. Plasma 25-hydroxyvitamin D concentration and metabolic syndrome among middle-aged and elderly chinese individuals. Diabetes Care 2009; 32: 1278-1283.

  12. Zhao G , Ford E, Li C, Kris-Etherton P, Etherton T, Balluz L. Independent associations of serum concentrations of 25-hydroxyvitamin D and parathyroid hormone with blood pressure among US adults. J Hypertens 2010; 28: 1821-1828.

  13. Reinehr T, Sousa G, Alexy U, Kersting M, Andler W. Vitamin D status and parathyroid hormone in obese children before and after weight loss. Eur J Endocrinol 2007; 157: 225-232.

  14. Bolland M, Grey A, Ames R, Mason B, Horne A, Gamble G, Reid R. The effects of seasonal variation of 25-hydroxyvitamin D and fat mass on a diagnosis of vitamin D sufficiency. Am J Clin Nutr 2007; 86: 959-964.

  15. Cheng S, Massaro J, Fox C, Larson M, Keyes M, McCabe E, Robins S, O’Donnell C, Hoffmann U, Jacques P, Booth S, Vasan R, Wolf M, Wang T. Adiposity cardiometabolic risk, and vitamin D status: The Framingham Heart Study. Diabetes 2010; 59: 242-248.

  16. Reis J, von Mhlen D, Kritz-Silverstein D, Wingard D, Barrett E. Vitamin D, parathyroid hormone levels and the prevalence of metabolic syndrome in community-dwelling older adults. Diabetes Care 2007; 30: 1549-1555.

  17. Kochupillai N. The physiology of vitamin D: Current concepts. Indian J Med Res 2008; 127: 256-262.

  18. Reis A, Hauache O, Velho G. Vitamin D endocrine system and the genetic susceptibility to diabetes, obesity and vascular disease. A review of evidence. Diabetes Metab 2005; 31: 318-325.

  19. Liu S, Song Y, Ford E, Manson J, Buring J, Ridker P. Dietary calcium, vitamin D, and the prevalence of metabolic syndrome in middle-aged and older US women. Diabetes Care 2005; 28: 2926-2932.

  20. Liu E, Meigs J, Pittas A, McKeown N, Economos C, Booth S, Jacques P. Plasma 25-hydroxyvitamin D is associated with markers of the insulin resistant phenotype in nondiabetic adults. J Nutr 2009; 139: 329-334.

  21. Bloomgarden Z. The American Diabetes Association’s 57th Annual Advanced Postgraduate Course. Diabetes Care 2011; 34: e1-6.

  22. Weng F, Shults J, Leonard M, Stallings V, Zemel B. Risk factors for low serum 25-hydroxyvitamin D concentrations in otherwise healthy children and adolescents. Am J Clin Nutr 2007; 86: 150-158.

  23. Sánchez A. Vitamina D: Actualización. Rev Med Rosario 2010; 76: 70-87.

  24. Zubieta V, Reza A. Vitamina D: Más allá del tratamiento de las enfermedades óseas. Rev Endocr Nutr 2009; 17: 4-6.

  25. Holick M. Optimal vitamin D status for the prevention and treatment of osteoporosis. Drugs Aging 2007; 24: 1017-1029.

  26. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.

  27. Hrebícek J, Janout V, Malincíková J, Horáková D, Cízek L. Detection of insulin resistance by simple quantitative insulin sensitivity check index QUICKI for epidemiological assessment and prevention. J Clin Endocrinol Metab 2002; 87: 144-147.

  28. García E, Violante R. ¿Cómo se diagnostica la obesidad y quién debe hacerlo? Rev Endocr Nutr 2004; 12: 91-95.

  29. Swales H, Wang T. Vitamin D and cardiovascular disease risk: emerging evidence. Curr Opin Cardiol 2010; 25: 513-517.

  30. Zhao G, Ford E, Li C. Associations of serum concentrations of 25-hydroxyvitamin D and parathyroid hormone with surrogate markers of insulin resistance among U.S. Adults Without Physician-Diagnosed Diabetes: NHANES, 2003-2006. Diabetes Care 2010; 33: 344-347.

  31. Bolland M, Grey A, Gamble G, Reid I. Association between primary hyperparathyroidism and increased body weight: A meta-analysis. J Clin Endocrinol Metab 2005; 90: 1525-1530.

  32. Michael B. Zemel and Xiaocun Sun: Vitamin D Modulation of adipocyte function. In: Holick M, ed. Vitamin D, physiology, molecular biology and clinical applications. Second edition. Boston MA; Humana Press, 2010: 345-358.

  33. Querales M, Cruces M, Rojas S, Sánchez L. Deficiencia de vitamina D: ¿Factor de riesgo de síndrome metabólico? Rev Med Chile 2010; 138: 1312-1318.




2020     |     www.medigraphic.com